RELATED STUDY
Case Report: Lennox-Gastaut Epileptic Encephalopathy Responsive to Cannabidiol Treatment Associated With a Novel de novo Mosaic SHANK1 Variant
Key Findings: This case report presents a pediatric patient with SHANK1 Gly126Arg variant and treatment-resistant epilepsy. He was treated with cannabidiol on a clinical trial and remained without seizures for more than 4 years after.
Type of Study: Meta-analysis
Study Sample Size: 1
Study Result: Positive
Study Location(s): Poland
Year of Pub: 2021
Cannabinoids Studied: Cannabidiol (CBD)
Phytocannabinoid Source: Unspecified
Chemotype: Chemotype III
Ligands Studied: Glutamate
Dosage: CBD (30 mg/kg/day)